Bicycle Therapeutics plc (BCYC) Revenue History
Annual and quarterly revenue from 2016 to present
BCYC Revenue Over Time (2016–2025)
BCYC Revenue Growth History
7 of 8 years with positive growth- FY2016 revenue growth
- N/A
- FY2017 revenue growth
- N/A
- FY2018 revenue growth
- +246.4%
- FY2019 revenue growth
- +93.4%
- FY2020 revenue growth
- -24.7%
- FY2021 revenue growth
- +12.6%
- FY2022 revenue growth
- +23.6%
- FY2023 revenue growth
- +86.5%
- FY2024 revenue growth
- +30.8%
- FY2025 revenue growth
- +105.8%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $887K | -91.1% |
| Q4 2025 | $48.0M | +1193.3% |
| Q3 2025 | $11.7M | +338.5% |
| Q2 2025 | $2.9M | -68.8% |
| Q1 2025 | $10.0M | -48.9% |
| Q4 2024 | $3.7M | -30.4% |
| Q3 2024 | $2.7M | -50.0% |
| Q2 2024 | $9.4M | -17.9% |
Multi-year avg. share of annual revenue by fiscal quarter
BCYC Revenue Analysis (2016–2025)
Current Revenue & Growth
As of June 21, 2026, Bicycle Therapeutics plc (BCYC) generated trailing twelve-month (TTM) revenue of $63.5 million, reflecting significant decline in growth of -91.1% year-over-year. The most recent quarter (Q1 2026) recorded $887,000 in revenue, down 98.2% sequentially.
Historical Growth Trajectory
BCYC's 5-year compound annual growth rate (CAGR) stands at +47.5%, indicating outstanding long-term growth trajectory. The 3-year CAGR of +71.2% exceeds the 5-year average, indicating an acceleration in the most recent period. Bicycle Therapeutics plc's highest annual revenue of $72.6 million was recorded in 2025, an all-time high.
Peer Comparison
Compared to Healthcare sector peers — including CYCN (-4.2% YoY), and AGIO (+78.3% YoY) — BCYC has underperformed the peer group in revenue growth. Compare BCYC vs CYCN →
BCYC Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| BCYCCurrent | $63M | -91.1% | +47.5% | -341.3% | |
 CYCN | $2M | -4.2% | -2.0% | -239.8% | |
 AGIO | $54M | +78.3% | - | -873.9% |
BCYC Historical Revenue Data (2016–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $72.6M | +105.8% | $72.6M | 100.0% | $-247,718,000 | -341.3% |
| 2024 | $35.3M | +30.8% | $-137,691,000 | -390.3% | $-209,872,000 | -595.0% |
| 2023 | $27.0M | +86.5% | $-129,520,000 | -480.1% | $-189,946,000 | -704.1% |
| 2022 | $14.5M | +23.6% | $14.5M | 100.0% | $-116,653,000 | -806.6% |
| 2021 | $11.7M | +12.6% | $11.7M | 100.0% | $-65,618,000 | -561.0% |
| 2020 | $10.4M | -24.7% | $-22,759,000 | -219.0% | $-51,960,000 | -500.1% |
| 2019 | $13.8M | +93.4% | $-11,739,000 | -85.1% | $-26,299,000 | -190.6% |
| 2018 | $7.1M | +246.4% | $-13,625,000 | -190.9% | $-21,746,000 | -304.7% |
| 2017 | $2.1M | - | $-9,806,000 | -476.0% | $-16,213,000 | -787.0% |
| 2016 | $0 | - | $-269,289 | - | $-13,493,410 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
BCYC — Frequently Asked Questions
Quick answers to the most common questions about buying BCYC stock.
Is BCYC's revenue growth accelerating or slowing?
BCYC revenue is declining -91.1% year-over-year. TTM revenue fell to $63M, contrasting with the 5-year CAGR of +47.5%. The reversal reflects either macro headwinds or company-specific challenges.
What is BCYC's revenue history from 2016 to 2026?
Bicycle Therapeutics plc (BCYC) revenue history spans 2016 to 2026. TTM revenue as of 2026 is $63M, growing at -91.1% YoY. The 5-year CAGR is +47.5%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is BCYC's long-term revenue growth rate (CAGR)?
Bicycle Therapeutics plc's 5-year revenue CAGR of +47.5% reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of -91.1% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for BCYC.
Why does BCYC's quarterly revenue fluctuate?
BCYC quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Bicycle Therapeutics plc's revenue data from 2016 to 2026 shows full historical quarterly detail on this page.
How is BCYC's revenue distributed by segment?
BCYC reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does BCYC's revenue compare to industry peers?
Bicycle Therapeutics plc (BCYC) with TTM revenue of $63M and -91.1% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.